- Details
- Description
-
Packaging Size56t/Bottle
-
Strength356mg
-
CompositonAcoramidis
-
TreatmentCardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)
-
Formtablet
-
BrandLuciAcor
-
Quantity Unit356mg*56t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Acoramidis
Acoramidis is a near-complete (>90%) transthyretin stabilizer, developed to mimic the protective properties of the naturally occurring T119M mutation, to treat transthyretin amyloid cardiomyopathy.
Acoramidis is used to treat cardiomyopathy (enlarged and thickened heart muscle) of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), to reduce death and hospitalization related to heart problems.
It is taken by mouth.The most common adverse reactions include diarrhea and upper abdominal pain.
Transthyretin Amyloid Cardiomyopathy
Indicated for cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization
712 mg (2 tablets) PO BID
Dosage Modifications
Renal impairment
- No clinically significant differences in pharmacokinetics observed
Hepatic impairment
- Effect of hepatic impairment on pharmacokinetics is unknown